Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on November 1, 2004

Published online before print August 17, 2004
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.1003498v1
76/5/1075    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boudreau, R. T. M.
Right arrow Articles by Lin, T.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boudreau, R. T. M.
Right arrow Articles by Lin, T.-J.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.1003498


Received for publication October 22, 2003.
Revised July 20, 2004.
Accepted for publication July 21, 2004.


Article

Phosphatase inhibition potentiates IL-6 production by mast cells in response to Fc{varepsilon}RI-mediated activation: involvement of p38 MAPK

Robert T. M. Boudreau *, David W. Hoskin *{dagger}, and Tong-Jun Lin *{ddagger}@

Departments of *Microbiology & Immunology, {dagger}Pathology, and {ddagger}Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada

@ To whom correspondence should be addressed. E-mail: tong-jun.lin{at}dal.ca.


   Abstract

Mast cells are crucial effector cells in the immune response through mediator secretion and release of cytokines. A coordinated balance between protein kinases and phosphatases plays an essential role in the regulation of mast cell mediator secretion. We have previously shown that treatment of mast cells with okadaic acid (OA), a protein phosphatase 2A (PP2A) inhibitor, results in a dose-dependent increase in interleukin (IL)-6 production. We show here for the first time a synergism between OA and immunoglobulin E (IgE)-mediated IL-6 secretion by murine bone marrow-derived mast cells (BMMC). Selective p38 mitogen-activated protein kinase (p38 MAPK) inhibition reduces OA and IgE-mediated IL-6 production. Regulation of p38 MAPK by PP2A was demonstrated, as OA treatment caused a dose-dependent increase in p38 MAPK phosphorylation. Antigen-mediated activation of murine mast cells also resulted in an increase in p38 MAPK phosphorylation, which was potentiated by cotreatment of the cells with OA. Lastly, in two mast cell lines (human mast cell-1 5C6 and murine MC/9) and primary-cultured murine BMMC, we show by coimmunoprecipitation an interaction between p38 MAPK and PP2A. These data support a role for PP2A through interaction with p38 MAPK in the regulation of IgE-dependent mast cell activation.

Key Words: mast cell • protein phosphatase 2A (PP2A) • p38 mitogen-activated protein kinase • Fc{varepsilon} receptor • cytokine




This article has been cited by other articles:


Home page
J. Dent. Res.Home page
C.S. Patil and K.L. Kirkwood
p38 MAPK Signaling in Oral-related Diseases
J. Dent. Res., September 1, 2007; 86(9): 812 - 825.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
Y. Liu, M. Zhu, K. Nishida, T. Hirano, and W. Zhang
An essential role for RasGRP1 in mast cell function and IgE-mediated allergic response
J. Exp. Med., January 22, 2007; 204(1): 93 - 103.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the Society for Leukocyte Biology.